Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.

Jacalyn Rosenblatt, MD, Zekui Wu, MD, Corrine Lenahan, MD, Adam Bissonnette, Baldev Vasir, PhD, Kenneth Miller, MD, Robin Joyce, MD, James Levine, MD, Ilene Galinsky, RN, Richard Stone, MD, Donald Kufe, MD, David Avigan, MD

Blood (2007) 110 (11): 1794.

https://doi.org/10.1182/blood.V110.11.1794.1794

Published: 2007

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Daniel J. DeAngelo, MD, PhD, Lewis B. Silverman, MD, Stephen Couban, MD, Suzanne Dahlberg, PhD, Philip C. Amrein, MD, Matthew D. Seftel, MD, A. Robert Turner, MD, Martha Wadleigh, MD, L. Andres Sirulnik, MD, PhD, Ilene Galinsky, RN, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2006) 108 (11): 1858.

https://doi.org/10.1182/blood.V108.11.1858.1858

Published: 2006

Journal Articles

Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.

Jennifer Rhodes, PhD, Adam Amsterdam, PhD, Karen Ho, Stefan Heinrichs, PhD, John P. Kanki, PhD, Jennifer E. O’Neil, PhD, Alejandro Gutierrez, MD, Keith McKenna, Hui Feng, PhD, Mark Fleming, MD, Donna Neuberg, ScD, Ilene Galinsky, RN, Richard M. Stone, MD, Nancy Hopkins, PhD, A. Thomas Look, MD

Blood (2006) 108 (11): 1405.

https://doi.org/10.1182/blood.V108.11.1405.1405

Published: 2006

Journal Articles

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

Valentina Nardi, MD, Tal Raz, PhD, Xinyu Chao, Catherine J. Wu, MD, Richard Stone, MD, Ilene Galinsky, RN, NP, Martha Wadleigh, MD, Michael W.N. Deininger, MD, PhD, George Church, PhD, Jun Zhu, PhD, George Q. Daley, MD, PhD

Blood (2006) 108 (11): 837.

https://doi.org/10.1182/blood.V108.11.837.837

Published: 2006

Journal Articles

Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.

Jacalyn Rosenblatt, MD, Richard Stone, MD, Corrine Lenahan, MD, Zekwui Wu, MD, Baldev Vasir, PhD, Daniel J. DeAngelo, MD, Ilene Galinsky, RN, Kenneth Miller, MD, James D. Levine, MD, Robin Joyce, MD, Donald Kufe, MD, David Avigan, MD

Blood (2005) 106 (11): 2788.

https://doi.org/10.1182/blood.V106.11.2788.2788

Published: 2005

NARROW

Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.

Email alerts

ASH Publications

American Society of Hematology

Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only